Akari Therapeutics Taps ADC Deal Veteran Vatnak Vat-Ho as CBO to Accelerate Oncology Partnerships

  • Vatnak Vat-Ho, with 20+ years in oncology and ADC deals, joins Akari as Chief Business Officer.
  • Vat-Ho has led transactions totaling $25B, including recent ADC payload collaborations with Exelixis and BioNTech.
  • Akari's lead candidate, AKTX-101, targets TROP2 with a novel RNA splicing-disrupting payload, PH1.
  • IND-enabling studies for AKTX-101 are underway, with a First-In-Human trial targeted for mid-2027.

Akari's appointment of Vat-Ho underscores the growing importance of payload innovation in the ADC space, where differentiation is key. With $25B in deal experience under his belt, Vat-Ho brings strategic firepower to Akari as it seeks to expand its PH1 platform through partnerships. The move comes as the oncology sector increasingly values modular payload technologies that can be paired with multiple targets, a trend Akari aims to capitalize on with its TROP2-targeted AKTX-101 and broader pipeline.

Partnership Velocity
Whether Vat-Ho can leverage his ADC payload experience to secure high-value collaborations for Akari's PH1 platform.
Clinical Milestones
The pace at which Akari advances AKTX-101 toward the clinic and demonstrates PH1's broader potential.
Capital Markets Strategy
How Vat-Ho's capital markets expertise will shape Akari's investor engagement and financing strategy.